Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles: 2020-2024

Historic Amortizatization of Intangibles for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $10.8 million.

  • Xeris Biopharma Holdings' Amortizatization of Intangibles changed negligibly% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $10.8 million for FY2024, which is negligibly% changed negligibly from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Amortizatization of Intangibles stood at $10.8 million for FY2024, which was down 0.00% from $10.8 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Amortizatization of Intangibles ranged from a high of $10.8 million in FY2022 and a low of -$84,000 during FY2020.
  • Over the past 3 years, Xeris Biopharma Holdings' median Amortizatization of Intangibles value was $10.8 million (recorded in 2024), while the average stood at $10.8 million.
  • Data for Xeris Biopharma Holdings' Amortizatization of Intangibles shows a peak YoY spiked of 1,871.45% (in 2022) over the last 5 years.
  • Xeris Biopharma Holdings' Amortizatization of Intangibles (Yearly) stood at -$84,000 in 2020, then soared by 754.76% to $550,000 in 2021, then surged by 1,871.45% to $10.8 million in 2022, then remained steady at $10.8 million in 2023, then remained steady at $10.8 million in 2024.